The treatment of Staphylococcus aureus skin and soft tissue infections faces several challenges, such as the increased incidence antibiotic-resistant strains fact that antibiotics available to treat methicillin-resistant S. present low bioavailability, are not easily metabolized, cause severe secondary effects. Moreover, besides susceptibility pattern isolates detected in vitro, during patient ...